February 10, 2011
To whom it may concern:
Company Name : TOHO HOLDINGS CO., LTD.
Representative : Norio Hamada /President and Representative Director(Securities Code: 8129 / First Section of Tokyo Stock Exchange)
Contact : Katsuya Kato, Corporate Officer andGeneral Manager of Corporate Communications Officeand Corporate Planning Office(TEL: 03-5259-9520)

Notice of the Integration of Dispensing Pharmacy Business in Niigata Prefecture and Hokuriku Area
TOHO HOLDINGS CO., LTD. is pleased to announce that the meeting of its Board of Directors held today (February 10,2011), resolved details of the business reorganization of the dispensing pharmacy business in Niigata Prefecture and Hokuriku
area. The details are as follows.
1. Purpose of the Business Reorganization
The Kyoso Mirai Group, with TOHO HOLDINGS as its core company, is a corporate group engaged in thedistribution of pharmaceutical and other medical products. It has been working toward maximizing its group synergy
through the active use of the managerial resources of all member companies under the group slogan, “Total Commitment
to Good Health.”
The Group has adopted a business management and control system under which the pharmaceutical wholesaling andthe dispensing pharmacy businesses are centered on TOHO PHARMACEUTICAL CO., LTD., a wholly owned
subsidiary of TOHO HOLDINGS (hereinafter “Toho Pharmaceutical”), and PharmaCluster Co., Ltd., another wholly
owned subsidiary of the Company (hereinafter “PharmaCluster”), respectively. The Company today decided toreorganize the dispensing pharmacy businesses in Niigata Prefecture and Hokuriku area, with the aim of
optimizing group-wide managerial resources and maximizing its corporate value, and in order to promptly respond to thedrastically changing business environment.
2. Outline of the Business Reorganization
Zenkaido Corporation (hereinafter “Zenkaido”), a wholly owned subsidiary of PharmaCluster shall merge with Chuo
Medical Co., Ltd. (“Chuo Medical” hereinafter), a wholly owned subsidiary of PharmaCluster, on April 1, 2011. Inaddition, Zenkaido shall change its trade name to Mirai Corporation at the same time.
3. Summary of the absorption type merger① Schedule of the Merger
February 10, 2011: Conclusion and approval of an absorption type merger agreement
March 23, 2011: Extraordinary shareholders’ meeting to approve the absorption type merger agreement (Planned)
April 1, 2011: Date for the merger (Planned)② Method of the Merger
Consolidation is to be carried out based on an absorption-type merger whereby Zenkaido is the surviving company
and Chuo Medical is the absorbed company, and Chuo Medical will be dissolved.
③ Details of the Allocation upon the Merger
There will be no issuance of new shares or an increase in capital stock at the time of the merger due to the fact thatthe merger is between wholly owned sub-subsidiaries of the Company.
1④ Outlines of the Parties involved in the Merger
Surviving company

Absorbed company(1) Company name

Zenkaido Corporation

Chuo Medical Co., Ltd.

(2) Business contents

Dispensing pharmacy business

Dispensing pharmacy business(3) Establishment

March 31, 1981

February 25, 1997

(4) Principal place of

1st Floor, 13Y Building 3-5 Heijima,2-646-107 Hakusanura､Chuo Ward, Niigata

business

Nishi Ward, Niigata City, Niigata

City, Niigata(5) Corporate

Takeshi Kurita / President

Takashi Ohi /President(6) Capital

36 million yen

50 million yen(7) Number of shares

900 shares

1,000 shares

representative

issued(8) Net sales

5,809 million yen（FY2010）

4,377 million yen（FY2010）(9) Net assets

1,023 million yen（FY2010）

541 million yen（FY2010）(10) Total assets

2,357 million yen（FY2010）

1,701 million yen（FY2010）(11) Fiscal year end

March 31

March 31(12) Major shareholders andPharmaCluster Co., Ltd.

100.0%

PharmaCluster Co., Ltd.

100.0%

equity holdings⑤ Effects of the Merger(1) Company nameMirai Corporation（A change in company name to Zenkaido
Corporation.(Planned)）(2) Business contents

Dispensing pharmacy business(3) Principal place of business1st Floor, 13Y Building 3-5 Heijima, Nishi Ward, Niigata City, Niigata(4) Corporate representative

Chairman: Takashi Ohi
President: Takeshi Kurita(5) Director

Senior Executive Managing Director: Kazuo Watanabe
Executive Managing Director: Hiroshi Nakashima
Executive Managing Director: Yukio Watanabe
Director: Yoshiro Fujishima
Director: Shinobu Hayashi
Director: Yosuke Matsumoto
Auditor: Mitsuru Kaneuchi(6) Corporate officer

Corporate officer: Hiro Seiji
Corporate officer: Tsuyoshi Takimiya
Corporate officer: Akinori Wakao(7) Capital36 million yen(8) Fiscal year endMarch 31

4. Impact on business performance
Impacts from the reorganization of the Group’s dispensing pharmacy business above on the Company’s consolidated
operating results are considered insignificant.

2